You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLofexidine
Accession NumberDB04948
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLofexidine is an alpha2-adrenergic receptor agonist. It can be used as a short acting anti-hypertensive, but is mostly used to help relieve symptoms of heroin or opiate withdrawal in opiate dependency. It is approved in the United Kingdom, but is still undergoing clinical trials in the United States.
Structure
Thumb
Synonyms
2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline
Lofexidina
Lofexidinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BritlofexBritannia
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lofexidine hydrochloride
Thumb
  • InChI Key: DWWHMKBNNNZGHF-UHFFFAOYNA-N
  • Monoisotopic Mass: 294.009346169
  • Average Mass: 295.593
DBSALT000829
Categories
UNIIUI82K0T627
CAS number31036-80-3
WeightAverage: 259.132
Monoisotopic: 258.03266843
Chemical FormulaC11H12Cl2N2O
InChI KeyInChIKey=KSMAGQUYOIHWFS-UHFFFAOYSA-N
InChI
InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
IUPAC Name
2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
SMILES
CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • 1,3-dichlorobenzene
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Imidolactam
  • Aryl halide
  • Aryl chloride
  • 2-imidazoline
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in addictions and substance abuse.
PharmacodynamicsLofexidine is an orally active imidazoline adrenergic alpha-2-receptor agonist; and is believed to have a high affinity for 2A receptor subtypes resulting in less anti-hypertensive activity than clonidine, a non-selective alpha-2-receptor agonist. Hypotension may occur in susceptible subjects, accompanied by a decrease in heart rate. Abrupt discontinuation of lofexidine has been, in some cases, associated with a transient increase in blood pressure to higher than pre-treatment levels. It selectively stimulates receptors in the brain that monitor catecholamine levels in the blood. These receptors close a negative feedback loop that begins with descending sympathetic nerves from the brain that control the production of catecholamines (epinephrine, also known as adrenaline, and norepinephrine) in the adrenal medulla. By fooling the brain into believing that catecholamine levels are higher than they really are, lofexidine causes the brain to reduce its signals to the adrenal medulla, which in turn lowers catecholamine production and blood levels. The result is a lowered heart rate and blood pressure. This central action is responsible for the suppression of opiate withdrawal symptoms.
Mechanism of actionLofexidine is an alpha2-adrenergic receptor agonist.
Related Articles
AbsorptionLofexidine is extensively absorbed and achieves peak plasma concentration at 3 hours after administration of a single dose. Bioavailability is over 90% following oral administration.
Volume of distributionNot Available
Protein binding80 to 90%
Metabolism

Lofexidine undergoes extensive metabolism in the liver and excretion is mainly by the kidney.

Route of eliminationNot Available
Half life11 hours
ClearanceNot Available
ToxicityLofexidine was tolerated at high dosage in singe dose toxicity studies in animals, the LD50 being >77 mg/kg. With repeat dosing in mice, rats and dogs symptoms related to the pharmacology of the drug (ataxia, sedation, tremor, unkempt appearance and exhaustion) appeared. Overdosage may cause hypotension, bradycardia and sedation.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.9582
Caco-2 permeable+0.539
P-glycoprotein substrateSubstrate0.7119
P-glycoprotein inhibitor INon-inhibitor0.9326
P-glycoprotein inhibitor IINon-inhibitor0.8089
Renal organic cation transporterInhibitor0.6897
CYP450 2C9 substrateNon-substrate0.744
CYP450 2D6 substrateNon-substrate0.6421
CYP450 3A4 substrateNon-substrate0.5055
CYP450 1A2 substrateInhibitor0.8023
CYP450 2C9 inhibitorNon-inhibitor0.739
CYP450 2D6 inhibitorInhibitor0.6616
CYP450 2C19 inhibitorNon-inhibitor0.6593
CYP450 3A4 inhibitorNon-inhibitor0.9304
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5075
Ames testNon AMES toxic0.7322
CarcinogenicityNon-carcinogens0.913
BiodegradationNot ready biodegradable0.996
Rat acute toxicity2.9567 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6244
hERG inhibition (predictor II)Non-inhibitor0.7293
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point221-223U.S. Patent 3,966,757.
Predicted Properties
PropertyValueSource
Water Solubility0.147 mg/mLALOGPS
logP3.31ALOGPS
logP2.66ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)7.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area33.62 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.41 m3·mol-1ChemAxon
Polarizability25.11 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,966,757.

General References
  1. Walsh SL, Strain EC, Bigelow GE: Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction. 2003 Apr;98(4):427-39. [PubMed:12653813 ]
External Links
ATC CodesN07BC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Lofexidine.
AcebutololAcebutolol may increase the hypotensive activities of Lofexidine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Lofexidine.
AliskirenLofexidine may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Lofexidine.
AmbrisentanLofexidine may increase the hypotensive activities of Ambrisentan.
AmifostineLofexidine may increase the hypotensive activities of Amifostine.
AmineptineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Amineptine.
AmitriptylineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Lofexidine.
ArotinololLofexidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
AtenololAtenolol may increase the hypotensive activities of Lofexidine.
BefunololLofexidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Lofexidine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lofexidine.
BenmoxinBenmoxin may increase the hypotensive activities of Lofexidine.
BepridilBepridil may increase the hypotensive activities of Lofexidine.
BetaxololBetaxolol may increase the hypotensive activities of Lofexidine.
BethanidineBethanidine may increase the hypotensive activities of Lofexidine.
BevantololLofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BimatoprostBimatoprost may increase the hypotensive activities of Lofexidine.
BisoprololBisoprolol may increase the hypotensive activities of Lofexidine.
BopindololLofexidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BosentanBosentan may increase the hypotensive activities of Lofexidine.
BretyliumBretylium may increase the hypotensive activities of Lofexidine.
BrimonidineLofexidine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Lofexidine.
BufuralolLofexidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololLofexidine may increase the hypotensive activities of Bupranolol.
CandesartanCandesartan may increase the hypotensive activities of Lofexidine.
CandoxatrilCandoxatril may increase the hypotensive activities of Lofexidine.
CaptoprilCaptopril may increase the hypotensive activities of Lofexidine.
CaroxazoneCaroxazone may increase the hypotensive activities of Lofexidine.
CarteololCarteolol may increase the hypotensive activities of Lofexidine.
CarvedilolCarvedilol may increase the hypotensive activities of Lofexidine.
CeliprololCeliprolol may increase the hypotensive activities of Lofexidine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Lofexidine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lofexidine.
CilazaprilCilazapril may increase the hypotensive activities of Lofexidine.
ClomipramineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Lofexidine.
CryptenamineCryptenamine may increase the hypotensive activities of Lofexidine.
CyclobenzaprineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Cyclobenzaprine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Lofexidine.
DebrisoquinDebrisoquin may increase the hypotensive activities of Lofexidine.
DeserpidineLofexidine may increase the hypotensive activities of Deserpidine.
DesipramineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Desipramine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Lofexidine.
DiazoxideDiazoxide may increase the hypotensive activities of Lofexidine.
DiltiazemDiltiazem may increase the hypotensive activities of Lofexidine.
DorzolamideDorzolamide may increase the hypotensive activities of Lofexidine.
DosulepinThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Dosulepin.
DoxazosinDoxazosin may increase the hypotensive activities of Lofexidine.
DoxepinThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Doxepin.
DuloxetineDuloxetine may decrease the antihypertensive activities of Lofexidine.
EfonidipineLofexidine may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Lofexidine.
EnalaprilatLofexidine may increase the hypotensive activities of Enalaprilat.
EpoprostenolEpoprostenol may increase the hypotensive activities of Lofexidine.
EprosartanEprosartan may increase the hypotensive activities of Lofexidine.
EsmirtazapineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Esmirtazapine.
EsmololLofexidine may increase the atrioventricular blocking (AV block) activities of Esmolol.
FelodipineFelodipine may increase the hypotensive activities of Lofexidine.
FenoldopamFenoldopam may increase the hypotensive activities of Lofexidine.
FosinoprilFosinopril may increase the hypotensive activities of Lofexidine.
FurazolidoneFurazolidone may increase the hypotensive activities of Lofexidine.
GuanabenzGuanabenz may increase the hypotensive activities of Lofexidine.
GuanadrelGuanadrel may increase the hypotensive activities of Lofexidine.
GuanethidineGuanethidine may increase the hypotensive activities of Lofexidine.
GuanfacineGuanfacine may increase the hypotensive activities of Lofexidine.
HexamethoniumLofexidine may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Lofexidine.
HydralazineHydralazine may increase the hypotensive activities of Lofexidine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Lofexidine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Lofexidine.
IloprostIloprost may increase the hypotensive activities of Lofexidine.
ImipramineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Imipramine.
IndapamideIndapamide may increase the hypotensive activities of Lofexidine.
IndenololLofexidine may increase the hypotensive activities of Indenolol.
IndoraminLofexidine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Lofexidine.
IproniazidIproniazid may increase the hypotensive activities of Lofexidine.
IrbesartanIrbesartan may increase the hypotensive activities of Lofexidine.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lofexidine.
IsradipineIsradipine may increase the hypotensive activities of Lofexidine.
LabetalolLabetalol may increase the hypotensive activities of Lofexidine.
LacidipineLofexidine may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Lofexidine.
LercanidipineLercanidipine may increase the hypotensive activities of Lofexidine.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Lofexidine.
LisinoprilLisinopril may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Lofexidine.
MacitentanLofexidine may increase the hypotensive activities of Macitentan.
ManidipineLofexidine may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Lofexidine.
MecamylamineMecamylamine may increase the hypotensive activities of Lofexidine.
MethyldopaMethyldopa may increase the hypotensive activities of Lofexidine.
Methylene blueMethylene blue may increase the hypotensive activities of Lofexidine.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Lofexidine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lofexidine.
MetipranololMetipranolol may increase the hypotensive activities of Lofexidine.
MetolazoneMetolazone may increase the hypotensive activities of Lofexidine.
MetoprololMetoprolol may increase the hypotensive activities of Lofexidine.
MianserinThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Mianserin.
MibefradilMibefradil may increase the hypotensive activities of Lofexidine.
MilnacipranMilnacipran may decrease the antihypertensive activities of Lofexidine.
MinaprineMinaprine may increase the hypotensive activities of Lofexidine.
MinoxidilMinoxidil may increase the hypotensive activities of Lofexidine.
MirtazapineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Mirtazapine.
MoclobemideMoclobemide may increase the hypotensive activities of Lofexidine.
MoexiprilMoexipril may increase the hypotensive activities of Lofexidine.
MolsidomineMolsidomine may increase the hypotensive activities of Lofexidine.
MoxonidineLofexidine may increase the hypotensive activities of Moxonidine.
NadololNadolol may increase the hypotensive activities of Lofexidine.
NaloxegolThe risk or severity of adverse effects can be increased when Lofexidine is combined with Naloxegol.
NebivololNebivolol may increase the hypotensive activities of Lofexidine.
NialamideNialamide may increase the hypotensive activities of Lofexidine.
NicardipineNicardipine may increase the hypotensive activities of Lofexidine.
NicorandilLofexidine may increase the hypotensive activities of Nicorandil.
NiguldipineLofexidine may increase the hypotensive activities of Niguldipine.
NilvadipineLofexidine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Lofexidine.
NisoldipineNisoldipine may increase the hypotensive activities of Lofexidine.
NitrendipineNitrendipine may increase the hypotensive activities of Lofexidine.
NitroprussideNitroprusside may increase the hypotensive activities of Lofexidine.
NortriptylineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Nortriptyline.
ObinutuzumabLofexidine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Lofexidine.
OlmesartanOlmesartan may increase the hypotensive activities of Lofexidine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Lofexidine.
OxprenololOxprenolol may increase the hypotensive activities of Lofexidine.
PargylinePargyline may increase the hypotensive activities of Lofexidine.
PenbutololPenbutolol may increase the hypotensive activities of Lofexidine.
PentoliniumPentolinium may increase the hypotensive activities of Lofexidine.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lofexidine.
PerindoprilPerindopril may increase the hypotensive activities of Lofexidine.
PhenelzinePhenelzine may increase the hypotensive activities of Lofexidine.
PheniprazinePheniprazine may increase the hypotensive activities of Lofexidine.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Lofexidine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lofexidine.
PhentolaminePhentolamine may increase the hypotensive activities of Lofexidine.
PinacidilLofexidine may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Lofexidine.
PirlindolePirlindole may increase the hypotensive activities of Lofexidine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Lofexidine.
PolythiazidePolythiazide may increase the hypotensive activities of Lofexidine.
PractololLofexidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PrazosinPrazosin may increase the hypotensive activities of Lofexidine.
PropranololPropranolol may increase the hypotensive activities of Lofexidine.
ProtriptylineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Protriptyline.
QuinaprilQuinapril may increase the hypotensive activities of Lofexidine.
QuinineQuinine may increase the hypotensive activities of Lofexidine.
RamiprilRamipril may increase the hypotensive activities of Lofexidine.
RasagilineRasagiline may increase the hypotensive activities of Lofexidine.
RemikirenRemikiren may increase the hypotensive activities of Lofexidine.
RescinnamineLofexidine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Lofexidine.
RiociguatLofexidine may increase the hypotensive activities of Riociguat.
RituximabLofexidine may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Lofexidine.
SaprisartanSaprisartan may increase the hypotensive activities of Lofexidine.
SelegilineSelegiline may increase the hypotensive activities of Lofexidine.
SelexipagLofexidine may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Lofexidine.
SitaxentanLofexidine may increase the hypotensive activities of Sitaxentan.
SotalolLofexidine may increase the atrioventricular blocking (AV block) activities of Sotalol.
SpiraprilSpirapril may increase the hypotensive activities of Lofexidine.
TadalafilTadalafil may increase the antihypertensive activities of Lofexidine.
TelmisartanTelmisartan may increase the hypotensive activities of Lofexidine.
TemocaprilLofexidine may increase the hypotensive activities of Temocapril.
TerlipressinTerlipressin may increase the hypotensive activities of Lofexidine.
TianeptineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Tianeptine.
TiboloneLofexidine may increase the hypotensive activities of Tibolone.
TicrynafenTicrynafen may increase the hypotensive activities of Lofexidine.
TimololTimolol may increase the hypotensive activities of Lofexidine.
TolazolineTolazoline may increase the hypotensive activities of Lofexidine.
ToloxatoneToloxatone may increase the hypotensive activities of Lofexidine.
TorasemideTorasemide may increase the hypotensive activities of Lofexidine.
TrandolaprilTrandolapril may increase the hypotensive activities of Lofexidine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lofexidine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Lofexidine.
TravoprostTravoprost may increase the hypotensive activities of Lofexidine.
TreprostinilTreprostinil may increase the hypotensive activities of Lofexidine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Lofexidine.
TrimazosinLofexidine may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Lofexidine.
TrimipramineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Trimipramine.
UdenafilUdenafil may increase the antihypertensive activities of Lofexidine.
UnoprostoneLofexidine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Lofexidine.
VardenafilVardenafil may increase the antihypertensive activities of Lofexidine.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Lofexidine.
XylometazolineLofexidine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Lofexidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Jin Y, Verstappen A, Elko E, Cammarata P, Yorio T: Effects of lofexidine, an alpha 2-adrenoreceptor agonist, on ocular blood flow and ion transport of rabbit iris-ciliary body. J Ocul Pharmacol. 1992 Spring;8(1):23-33. [PubMed:1357064 ]
  2. Strang J, Bearn J, Gossop M: Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict. 1999 Fall;8(4):337-48. [PubMed:10598217 ]
  3. Erb S, Hitchcott PK, Rajabi H, Mueller D, Shaham Y, Stewart J: Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology. 2000 Aug;23(2):138-50. [PubMed:10882840 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24